Clinical Trial

Health Union Launches First-of-Its-Kind People-based Data Engine

ILLUMINÉ™ Harnesses the Power of Community to Build Privacy-first, Persona-Based Media Solutions PHILADELPHIA, Sept. 3, 2024 /PRNewswire/ -- Health Union,…

4 months ago

Somite Therapeutics Announces Round Extension with Astellas Venture Management and Montage Ventures Joining as Board Observers

To comply with academic institution guidelines, the founders' academic affiliations and roles are listed only at the end of the…

4 months ago

PhaseV to Present at Upcoming Healthcare, Pharma and Technology Events

New Research and Case Studies Demonstrate Effectiveness of Machine Learning-Based Platforms for Adaptive Clinical Trial Design and Analysis BOSTON, Sept.…

4 months ago

Movano Health Advances to Final Phase of FDA Review Process for EvieMED Ring

Following the positive outcome of a recent agency meeting, the Company will continue to work closely with the FDA to…

4 months ago

Humonix Bio Announces Appointment of Thurein Htoo as Chairman of the Board of Directors and Welcomes Christie Markowitz as New Independent Board Director

ALBANY, NY / ACCESSWIRE / September 3, 2024 / Humonix Biosciences, Inc., a leading specialty pharmaceutical research company, is pleased…

4 months ago

AngioDynamics Announces CE Mark Approval in Europe for the Auryon System

Regulatory approval enables entry of Auryon Atherectomy System in European marketLATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative…

4 months ago

Y-mAbs to Participate in Upcoming Investor Conferences in September

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…

4 months ago

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

ATLANTA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet…

4 months ago

Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b Trial in Blood Cancer (Diffuse Large B-Cell Lymphoma)

10 patients have been treated to date with azer-cel in the Phase 1b diffuse large B-cell lymphoma (DLBCL) trial Cohort…

4 months ago

Better Choice Company Signs Definitive Agreement to Acquire SRx Health for Approximately $125 Million

Combined company will emerge as a leading global health and wellness company by providing products and solutions for families to…

4 months ago